PaxMedica (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients – InvestorBrandNetwork (IBN) Content Platform

Autism (“ASD”) is a global problem, with no generally accepted treatment. In the UK alone, between 1998 and 2018, research has found a greater than 780% increase in the number of autism cases
PaxMedica is focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms
The ASD therapeutics market was valued at $2.01 billion in 2023 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9%
There is currently no approved pharmacologic treatment targeting the cause and symptoms. Current treatments only address the condition’s symptoms rather than targeting the pathophysiology itself

Researchers used to believe that autism spectrum disorder only affected one in 2,500 children – today, that estimation is closer to one in 36 children. Between 1998 and 2018, research has found more than a 780% increase in the number of autism cases in the United Kingdom. This significant increase is partially due to the deeper understanding and awareness of autism and the number of physicians who can diagnose the condition (https://ibn.fm/o5oTZ).

Autism spectrum disorder (“ASD”) is a developmental disorder affecting how individuals interact with other people, behavior, communication, and learning. This disorder can be diagnosed at any age, but symptoms often appear in the first two years of life. There is currently no approved pharmacologic treatment targeting the cause and symptoms. Current treatments only address the condition’s symptoms rather than targeting the pathophysiology itself.

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms, is on a promising path to address the unmet medical needs of ASD, bringing hope to millions. Anti-purinergic therapies target…